Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
3.63M | 3.73M | 2.66M | 2.51M | 3.86M | 3.48M | Gross Profit |
3.04M | 3.12M | -1.03M | -1.21M | 781.70K | 458.00K | EBIT |
-2.70M | -2.38M | -2.92M | -2.61M | -1.43M | -1.80M | EBITDA |
-2.09M | -1.51M | -2.53M | -1.84M | -833.84K | -672.88K | Net Income Common Stockholders |
-2.36M | -2.07M | -2.59M | -1.97M | -924.24K | -1.33M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.48M | 2.52M | 2.18M | 4.70M | 1.71M | 1.92M | Total Assets |
5.50M | 5.13M | 5.18M | 7.99M | 5.33M | 5.92M | Total Debt |
1.60M | 989.28K | 1.09M | 1.31M | 1.43M | 1.62M | Net Debt |
115.47K | -1.53M | -787.15K | -376.91K | -265.40K | -288.21K | Total Liabilities |
2.38M | 2.07M | 2.14M | 2.06M | 2.26M | 2.50M | Stockholders Equity |
3.12M | 3.06M | 3.04M | 5.94M | 3.08M | 3.42M |
Cash Flow | Free Cash Flow | ||||
-1.52M | -1.22M | -1.58M | -1.08M | 21.63K | -321.38K | Operating Cash Flow |
-1.51M | -1.16M | -1.42M | -967.51K | 54.98K | -283.23K | Investing Cash Flow |
-56.85K | -57.55K | -151.94K | -115.31K | -33.35K | -38.16K | Financing Cash Flow |
536.63K | 1.57M | -952.96K | 4.05M | -281.87K | 1.03M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
46 Neutral | AU$5.01M | ― | -117.20% | ― | 2.91% | 13.51% | |
€4.50M | ― | -321.94% | ― | ― | ― | ||
47 Neutral | AU$5.31M | ― | -375.15% | ― | -59.01% | 17.06% | |
41 Neutral | AU$10.31M | ― | -98.08% | ― | -7.44% | 30.34% | |
39 Underperform | AU$10.98M | ― | -61.15% | ― | 35.63% | 18.55% | |
38 Underperform | AU$8.54M | ― | -191.40% | ― | ― | 19.74% |
Uscom Limited released its quarterly cash report for the period ending March 31, 2025, showing a 14% increase in customer receipts compared to the previous quarter, despite a challenging global trade environment. The company’s operational highlights include significant clinical achievements, strengthened partnerships with Foxconn and SinoPharm, and the establishment of a new subsidiary in China to support expansion. With new products and strategic partnerships, Uscom is well-positioned for growth in anticipation of a more stable global economic environment.